Mississippi SB2561 authorizes the State Department of Health to select a consortium to conduct a clinical trial for ibogaine, aiming to secure FDA.
Mississippi SB2561, known as the Ibogaine Drug Development Clinical Trial Act, authorizes the State Department of Health to select a consortium to conduct a drug development clinical trial for ibogaine. The goal is to secure FDA approval for ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and other neurological or mental health conditions. The bill outlines the process for selecting a consortium, including the submission of a proposal detailing the trial strategy, team composition, and financial plans.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.